members of the Association of International Pharmaceutical Manufacturers in Hungary have decided not to raise their prices in 1996, following the planned state drug price rise of 35%-40% within the next month or so, which includes a 7.4% manufacturers' price rise, reports MTI Econews (Marketletter January 29).
The AIPM has said that delays in introducing the new drug price reimbursement system in Hungary means extra expenditure of 2 billion forint ($13.7 million) for the National Health Insurance Fund.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze